FGF1
ENSG00000113578
Target class
Secreted protein
Chromosome
5
Approved drugs
0
Clinical candidates (approved and in development)
5
- Approved drugs
- 0
- Clinical candidates (approved and in development)
- 5
- Chemical probe available
- Yes
- Target name
- FGF1
- Gene name
- Fibroblast growth factor 1
- Gene symbol
- FGF1
- Previous gene symbols
- FGFA
- Protein name
- Fibroblast growth factor 1 (FGF-1) (Acidic fibroblast growth factor) (aFGF) (Endothelial cell growth factor) (ECGF) (Heparin-binding growth factor 1) (HBGF-1)
- AFGF
- ECGF
- ECGFA
- ECGFB
- HBGF1
- ECGF-beta
- FGF-alpha
- GLIO703
- Gene biotype
- Protein coding
- Gene family
- Receptor ligands|Fibroblast growth factor family
- Target class
- Secreted protein
- Target type
- Human gene
- Tissues expressed in
- 38
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 225.99
- Tissue specificity (Gini)
- 0.741
- Tissue specificity (tau)
- 0.894
- KEGG gene identifiers
- hsa:2246
- Protein interaction confidence
- 0.826113
- Protein interaction partners
- 53
- R-HSA-109704
- R-HSA-1257604
- R-HSA-1839122
- R-HSA-1839130
- R-HSA-190322
- R-HSA-190370
- R-HSA-190371
- R-HSA-190372
- R-HSA-190373
- R-HSA-190375
- R-HSA-190377
- R-HSA-2033519
- R-HSA-2219530
- R-HSA-5654219
- R-HSA-5654221
- R-HSA-5654227
- R-HSA-5654228
- R-HSA-5654687
- R-HSA-5654688
- R-HSA-5654689
- R-HSA-5654693
- R-HSA-5654695
- R-HSA-5654699
- R-HSA-5654700
- R-HSA-5654704
And 15 more, listed on the interactive page.
- End position
- 142698070
- Start position
- 142592166
- Chromosome
- 5
- Strand
- Reverse
- Secreted. Cytoplasm. Cytoplasm, cell cortex. Cytoplasm, cytosol. Nucleus. Note=Lacks a cleavable signal sequence. Within the cytoplasm, it is transported to the cell membrane and then secreted by a non-classical pathway that requires Cu(2+) ions and S100A13. Secreted in a complex with SYT1 (By similarity). Binding of exogenous FGF1 to FGFR facilitates endocytosis followed by translocation of FGF1 across endosomal membrane into the cytosol. Nuclear import from the cytosol requires the classical nuclear import machinery, involving proteins KPNA1 and KPNB1, as well as LRRC59. .
- Nucleoplasm
- Tissue specificity (tau)
- 0.894314
- Expression inequality (Gini)
- 0.741104
Expression in transcripts per million
- Brain - Spinal cord (cervical c-1)
- 225.99
- Brain - Substantia nigra
- 167.25
- Nerve - Tibial
- 122.21
- Brain - Hippocampus
- 109.57
- Brain - Amygdala
- 105.28
Expression in transcripts per million
- Brain - Spinal cord (cervical c-1)225.99
- Brain - Substantia nigra167.25
- Nerve - Tibial122.21
- Brain - Hippocampus109.57
- Brain - Amygdala105.28
- Brain - Putamen (basal ganglia)102.99
- Brain - Hypothalamus95.25
- Brain - Caudate (basal ganglia)86.85
- Brain - Nucleus accumbens (basal ganglia)56.5
- Brain - Frontal Cortex (BA9)47.53
- Brain - Anterior cingulate cortex (BA24)46.12
- Brain - Cortex43.42
- Brain - Cerebellum40.33
- Brain - Cerebellar Hemisphere38.51
- Kidney - Cortex37.96
- Artery - Coronary30.66
- Artery - Aorta24.69
- Artery - Tibial17.16
- Adipose - Visceral (Omentum)11.48
- Heart - Left Ventricle9.51
- Heart - Atrial Appendage9.02
- Kidney - Medulla9
- Cells - Cultured fibroblasts8.31
- Pituitary8.03
- Breast - Mammary Tissue4.29
And 29 more, listed on the interactive page.
- GO:0008284
- GO:0008543
- GO:0009653
- GO:0010595
- GO:0030335
- GO:0032148
- GO:0034605
- GO:0042060
- GO:0043406
- GO:0045542
- GO:0045766
- GO:0045944
- GO:0051781
- GO:0060681
- GO:0070374
- GO:0072163
- GO:1901509
- GO:1902533
- GO:1903672
- GO:2000544
- GO:0005576
- GO:0005654
- GO:0005829
- GO:0005104
- GO:0005178
- GO:0005515
- GO:0008083
- GO:0008201
- GO:0044548
Related records
Trials (61)
- A Multi-center Evaluation of Aldafermin in a Randomized, Double-blind, Placebo-controlled Study in Subjects With Primary Sclerosing Cholangitis.
- A Multiple Ascending Dose Study to Evaluate Safety and Tolerability of BFKB8488A in Participants With Type 2 Diabetes Mellitus and Participants With Non-Alcoholic Fatty Liver Disease
- A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder
- A Phase II Trial of Leuprolide + Flutamide + Suramin in Untreated Poor Prognosis Prostate Carcinoma
- A Phase III PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related HCC After Surgical Resection
- A Study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
- A Study of Experimental Medication BMS-986036 Given to Healthy Participants
- A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis
- A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis
- A Study of NGM282 in Patients With Primary Sclerosing Cholangitis
- A Study to Evaluate BMS-986036 in Obese Adults With Type-2 Diabetes
- A Study to Evaluate the Drug Levels and Safety of Pegbelfermin in Healthy Overweight and Obese Chinese and Korean Participants
- A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986036 in Participants With Normal Liver Function and Participants With Moderate and Severe Liver Impairment
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis
- A Study to Test the Effects of BMS-986036 on the Body in Healthy Japanese and Non-Japanese Subjects
- A Sub-study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
- Aldafermin (NGM282) for Chronic Diarrhea Due to Bile Acid Malabsorption (BAM)
- An Investigational Study to Evaluate Experimental Medication BMS-986036 in Participants With Different Levels of Kidney Function
- Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors
- Companion Protocol for ¹³C-Methacetin Breath Tests in BMS: NCT03486899, NCT03486912 Referenced Trials
Drugs (6)
- Aldafermin FGF1/KLB activator
- Fazpilodemab FGF1/KLB agonist
- Muparfostat Acidic fibroblast growth factor inhibitor
- Pegbelfermin FGF1/KLB agonist
- Suramin Acidic fibroblast growth factor inhibitor
- Suramin hexasodium Acidic fibroblast growth factor inhibitor